MA46459B1 - Méthode de traitement de lésions rénales aiguës - Google Patents
Méthode de traitement de lésions rénales aiguësInfo
- Publication number
- MA46459B1 MA46459B1 MA46459A MA46459A MA46459B1 MA 46459 B1 MA46459 B1 MA 46459B1 MA 46459 A MA46459 A MA 46459A MA 46459 A MA46459 A MA 46459A MA 46459 B1 MA46459 B1 MA 46459B1
- Authority
- MA
- Morocco
- Prior art keywords
- kidney injury
- acute kidney
- treatment method
- injury treatment
- acute
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Vascular Medicine (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662404390P | 2016-10-05 | 2016-10-05 | |
| PCT/US2017/055400 WO2018067857A1 (en) | 2016-10-05 | 2017-10-05 | Methods of treating acute kidney injury |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA46459A MA46459A (fr) | 2019-08-14 |
| MA46459B1 true MA46459B1 (fr) | 2021-03-31 |
Family
ID=60153507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA46459A MA46459B1 (fr) | 2016-10-05 | 2017-10-05 | Méthode de traitement de lésions rénales aiguës |
Country Status (33)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA122237C2 (uk) | 2015-10-07 | 2020-10-12 | Мітобрідж, Інк. | Агоністи ppar, сполуки, фармацевтичні композиції та способи їх застосування |
| MX380531B (es) * | 2016-04-13 | 2025-03-12 | Mitobridge Inc | Agonistas del receptor activado por proliferador de peroxisoma (ppar), compuestos, composiciones farmacéuticas y métodos para usar los mismos. |
| ES2887008T3 (es) | 2016-10-05 | 2021-12-21 | Mitobridge Inc | Formas cristalinas y de sal de compuestos agonistas del PPAR |
| EP3999060A1 (en) | 2019-07-19 | 2022-05-25 | Vifor (International) Ag | Ferroportin-inhibitors for the use in the prevention and treatment of kidney injuries |
| US11634387B2 (en) | 2019-09-26 | 2023-04-25 | Abionyx Pharma Sa | Compounds useful for treating liver diseases |
| EP4305024A1 (en) * | 2021-03-08 | 2024-01-17 | Abionyx Pharma SA | Compounds useful for treating liver diseases |
| WO2022189856A1 (en) | 2021-03-08 | 2022-09-15 | Abionyx Pharma Sa | Compounds useful for treating liver diseases |
| CN115813901B (zh) * | 2022-10-20 | 2024-10-22 | 南京市儿童医院 | 3-苯基戊二酸衍生物类小分子在制备防治顺铂诱导的急性肾损伤药物中的应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0414534B8 (pt) * | 2003-09-19 | 2021-05-25 | Janssen Pharmaceutica Nv | ácidos 4-((fenoxialquila)tio)-fenoxiacéticos e análogos e composição farmacêutica compreendendo-os |
| US7323480B2 (en) * | 2004-05-25 | 2008-01-29 | Metabolex, Inc. | Substituted triazoles as modulators of PPAR and methods of their preparation |
| RU2320341C1 (ru) * | 2006-06-13 | 2008-03-27 | Государственное учреждение Научный центр реконструктивной и восстановительной хирургии Восточно-Сибирского научного центра Сибирского отделения Российской Академии медицинских наук | Средство для лечения острой обструкции верхних мочевыводящих путей |
| KR20090071829A (ko) * | 2007-12-28 | 2009-07-02 | 주식회사 머젠스 | 신장질환의 치료 및 예방을 위한 약제 조성물 |
| KR20110091680A (ko) * | 2008-10-17 | 2011-08-12 | 메타볼렉스, 인코포레이티드 | 작고 조밀한 ｌｄｌ 입자를 감소시키는 방법 |
| US7928067B2 (en) * | 2009-05-14 | 2011-04-19 | Ischemix Llc | Compositions and methods for treating ischemia and ischemia-reperfusion injury |
| WO2014138738A1 (en) * | 2013-03-08 | 2014-09-12 | Abbive Inc. | Methods of treating acute kidney injury |
| EP2981522A4 (en) * | 2013-04-05 | 2016-08-31 | Salk Inst For Biological Studi | PPAR AGONISTS |
| EP2862574A1 (en) * | 2013-10-15 | 2015-04-22 | Sanofi | {4-[5-(3-chloro-phenoxy)-oxazolo[5,4 d]pyrimidin-2-yl]-2,6-dimethyl-phenoxy}-acetic acid for use in the prevention or treatment of acute kidney injury |
| CN105917229B (zh) * | 2013-12-03 | 2019-04-26 | 阿斯图特医药公司 | 用于肾损伤和肾衰竭的诊断和预后的方法和组合物 |
| WO2016057656A1 (en) * | 2014-10-08 | 2016-04-14 | Mitobridge, Inc. | Ppar-delta agonists for use for treating mitochondrial, vascular, muscular, and demyelinating diseases |
| WO2016057658A1 (en) * | 2014-10-08 | 2016-04-14 | Mitobridge, Inc. | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof |
| UA122237C2 (uk) * | 2015-10-07 | 2020-10-12 | Мітобрідж, Інк. | Агоністи ppar, сполуки, фармацевтичні композиції та способи їх застосування |
-
2017
- 2017-10-05 WO PCT/US2017/055400 patent/WO2018067857A1/en not_active Ceased
- 2017-10-05 JP JP2019518278A patent/JP7065839B2/ja active Active
- 2017-10-05 CN CN201780062021.8A patent/CN109789117B/zh active Active
- 2017-10-05 RU RU2019111421A patent/RU2753607C2/ru active
- 2017-10-05 JO JOP/2019/0056A patent/JOP20190056B1/ar active
- 2017-10-05 LT LTEP17787773.5T patent/LT3522880T/lt unknown
- 2017-10-05 EP EP17787773.5A patent/EP3522880B1/en active Active
- 2017-10-05 US US16/334,384 patent/US20210283116A1/en not_active Abandoned
- 2017-10-05 SG SG11201901925RA patent/SG11201901925RA/en unknown
- 2017-10-05 ES ES17787773T patent/ES2859487T3/es active Active
- 2017-10-05 DK DK17787773.5T patent/DK3522880T3/da active
- 2017-10-05 MA MA46459A patent/MA46459B1/fr unknown
- 2017-10-05 KR KR1020197012516A patent/KR20190062502A/ko not_active Ceased
- 2017-10-05 UA UAA201904011A patent/UA124019C2/uk unknown
- 2017-10-05 HU HUE17787773A patent/HUE053557T2/hu unknown
- 2017-10-05 SM SM20210111T patent/SMT202100111T1/it unknown
- 2017-10-05 TW TW106134387A patent/TWI778982B/zh active
- 2017-10-05 CA CA3036723A patent/CA3036723A1/en active Pending
- 2017-10-05 PT PT177877735T patent/PT3522880T/pt unknown
- 2017-10-05 PL PL17787773T patent/PL3522880T3/pl unknown
- 2017-10-05 MD MDE20190903T patent/MD3522880T2/ro unknown
- 2017-10-05 SI SI201730653T patent/SI3522880T1/sl unknown
- 2017-10-05 RS RS20210203A patent/RS61573B1/sr unknown
- 2017-10-05 HR HRP20210294TT patent/HRP20210294T1/hr unknown
- 2017-10-05 AU AU2017340760A patent/AU2017340760B2/en active Active
- 2017-10-05 MY MYPI2019001558A patent/MY192385A/en unknown
- 2017-10-05 MX MX2019003949A patent/MX387518B/es unknown
- 2017-10-05 BR BR112019005539A patent/BR112019005539A2/pt not_active Application Discontinuation
-
2019
- 2019-03-20 ZA ZA2019/01743A patent/ZA201901743B/en unknown
- 2019-04-01 IL IL265749A patent/IL265749A/en unknown
- 2019-04-03 PH PH12019500725A patent/PH12019500725A1/en unknown
- 2019-05-03 CO CONC2019/0004561A patent/CO2019004561A2/es unknown
-
2021
- 2021-02-23 CY CY20211100148T patent/CY1124759T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA46459B1 (fr) | Méthode de traitement de lésions rénales aiguës | |
| EP3813647A4 (en) | MULTIMODAL STIMULATION FOR TREMOR TREATMENT | |
| MA49760B1 (fr) | Mavacamten pour l'utilisation dans le traitement de la cardiomyopathie hypertrophique | |
| EP3644996A4 (en) | METHOD OF TREATMENT FOR HUNTINGTON'S MORBUS | |
| EA201790305A1 (ru) | КОМБИНИРОВАННАЯ ТЕРАПИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ МОНОКЛОНАЛЬНЫХ АНТИТЕЛ К N3pGlu АБЕТА И ИНГИБИТОРА BACE | |
| EA201990296A1 (ru) | Антитела против siglec-7 для лечения рака | |
| EA201791736A1 (ru) | Комбинированная терапия для лечения рака | |
| EA201992546A1 (ru) | Средства на основе антител к cd33 | |
| MA47408B1 (fr) | Traitement du cancer | |
| BR112018014222A2 (pt) | método de tratamento da glomerulopatia c3 | |
| EA201790142A1 (ru) | Лечение лейкоза ингибиторами гистондеацетилазы | |
| MX2016010173A (es) | Metodos de tratamiento de enfermedad de alzheimer. | |
| EP3686818A4 (en) | WATER TREATMENT SYSTEM | |
| MA52024A (fr) | Système de traitement de l'eau | |
| EA201692472A1 (ru) | Соединения для лечения рака мозга | |
| EA201791101A1 (ru) | Способы лечения рассеянного склероза | |
| EA201890878A1 (ru) | Способ лечения медуллобластомы с помощью ингибитора ezh2 | |
| EA201792610A1 (ru) | Способ лечения неврологического заболевания | |
| MA40607B1 (fr) | Traitements médicaux à base d'anamoréline | |
| JOP20190190A1 (ar) | معالجة سرطان | |
| EA201890347A1 (ru) | Антитела и исследования для обнаружения cd37 | |
| EP3775171A4 (en) | METHODS OF TREATMENT OF MINIMAL RESIDUAL CANCER | |
| MA44836A (fr) | Procédés de traitement du syndrome polykystique des reins | |
| EP3407858A4 (en) | METHOD FOR TREATING THE APPEARANCE OF THINNING HAIR | |
| EA202090266A1 (ru) | Ингибиторы mpo для применения в медицине |